# Dyslipidemia (ATPIII)

 Normal Cholesterol Levels TC < 200LDL <100HDL > 40 men, > 50 womenTG <150 Non-HDL-C goal 30 more than the LDL-C goal Calculate by (TC - HDL-C = non-HDL-C) 1st line treatment for dyslipidemia Statin therapy ATP III Risk Stratification for Dyslipidemia goals: Low risk (0-1 risk factor) LDL-C goal < 160 ATP III Risk Stratification for Dyslipidemia goals: Mod. risk (2+ risk factors) If 10-year Framingham risk is < 10%: LDL-C goal < 130 ATP III Risk Stratification for Dyslipidemia goals: Mod./High risk (2+ risk factors) If 10-yr. Framingham risk is 10-20%:  LDL-C goal <130, but <100 option ATP III Risk Stratification for Dyslipidemia goals: High risk (3+, CHD, or CHD equivalent risk factor) LDL-C goal <100, option <70 ATP III CHD risk equivalents DM, Carotid artery disease, AAA, PVD/PAD, or Multiple risk factors (FRAS >20%) ATP III Cholesterol Screening Begin at age 20, q5y if normal. Annually if abnl. ATP III goals for cholesterol treatment Target LDL first, then non-HDL-C (which targets TG's).  * Unless TG's dangerously high (>500), then start with TG treatment. Framingham Traditional Risk Factors affecting LDL-C goals Smoking, Age (men >/= 45, women >/= 55), HTN (>/= 140/90 or on meds), low HDL-C, Fm Hx of premature CHD (male <55y, female <65y) Definition of Myopathy (in consideration of statin therapy) c/o myalgia, weakness, cramps +  CK >10x ULN Definition of rhabdomyolosis (in consideration of statin therapy) CK > 10,000 or > 10x ULN  + Increased creatinine or need for IV hydration OBTAIN BASELINE CK IN HIGH RISK PATIENTS (liver dz, renal dz, polypharmacy) Statins -statin lower LDL by 30-55%, Crestor best, then Lipitor Risk of myopathy/rhabdo./liver fx but no need for routine monitoring of LFT's once initiated.  Contraind. in pregnancy, concurrent liver dz "Rule of 6" Expect 6% reduction in LDL-C with each doubling of statin dose. Authorwcameron ID200342 Card SetDyslipidemia (ATPIII) DescriptionNCEP ATP III Guidelines for Dyslipidemia Updated2013-02-14T00:06:07Z Show Answers